Mineralys Therapeutics, Inc. Common Stock(MLYS)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

MLYS iron condor setups MLYS expected move MLYS IV rank history MLYS Fibonacci levels MLYS insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MLYS $25.73 —
Snapshot
$25.73
52-Week Range
$22.30 – $47.65
YTD
-27.95%
IV Rank (30D)
29.75
Straddle Price
$3.97
P/C Vol Ratio
1.14
Market Cap
$2.4B
Fair Value
+30.4% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.35
Cost of Equity (CAPM)12.40% (VRP-adj)
WACC11.93%
Volatility Risk Premium+18.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-63.4%
Book / Price25.9%
Debt / Equity0.18
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$27.14 (Market Anchor value)
SMA 20 / Bollinger Mid$28.00
Bollinger Width / SMA2078.3% (drives anchor stability)
Net Debt$-0.0B
Market Cap$2B
Peers used for multiples: ALGN, AMGN, APLS, KYMR, LLY, REGN, UNH, UTHR
Blended Fair Value
$33.62
Deviation
+30.4%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 25.1× · 7 peers
Peer EV/EBITDA n/a 0% median 16.3× · 7 peers
Peer P/B $33.62 100% median 4.9× · 8 peers
Peer P/S n/a 0% median 5.5× · 8 peers
Market Anchor (SMA50) $27.14 0% stability 0% (BB-width)
Options Expected (B-L 30d) $25.84 0% 7 strikes · skew -0.02
As of 2026-09-25 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$2.4B

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduc…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -0.91% 3
Feb +5.45% 4
Mar +10.62% 4
Apr -4.29% 4
May +5.42% 4
Jun -4.64% 4
Jul +0.18% 4
Aug -2.30% 4
Sep +2.53% 4
Oct +0.46% 3
Nov -2.69% 3
Dec -0.27% 3
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $27.99
SMA 50: $27.11
SMA 200: $28.72
Current: $25.76
EMA 12: $27.59
EMA 26: $27.59
MACD: 0.0078 | Signal: -0.3253
BULLISH
ADX (14): 15.06
RANGE
+DI: 21.56
−DI: 27.53

Momentum Oscillators

RSI (14): 41.33
NEUTRAL
Stoch %K: 8.49
Stoch %D: 23.67
Williams %R: -91.89

Volume & Volatility

BB Upper: $31.10
BB Lower: $24.89
NEUTRAL
OBV: 17,540,227
Vol SMA 20: 1,386,256
Vol ROC: -58.90%
ATR: $1.52
True Range: $1.49
HV 20: 76.6%
HV 30: 65.8%
HV 60: 52.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis

LLM Stock Analysis Report - MLYS

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Technical indicators suggesting a potential breakout
  • Positive news sentiment around clinical trial results and licensing agreements
  • Low volatility compared to market, indicating a relatively safe investment opportunity

Primary risks:

  • High IV premium vs HV30, indicating potentially rich options prices
  • Divergent signals between technical indicators and news headlines

Investment thesis: MLYS is poised for a breakout due to the recent positive clinical trial results and licensing agreements. The low volatility suggests a relatively safe entry point, but investors should be cautious of the high IV premium.

Recent news sentiment impact: Positive news headlines have contributed to the bullish tone, with 4 out of 6 articles having a positive sentiment.

Technical Analysis

Trend Direction: Short-term: NEUTRAL (no clear trend), Medium-term: BULLISH ( SMA50 above SMA20 and SMA200), Long-term: BEARISH (SMA200 below SMA50 and SMA20)

Support/Resistance Levels:

  • Upper resistance: $27.92
  • Middle support/resistance: $26.72
  • Lower support: $25.51

Momentum Signals:

  • RSI (14): 40.01 (neutral)
  • MACD: -0.18 / Signal: -0.07 / Histogram: -0.10 (bearish)
  • Bollinger Bands position: neutral

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines surrounding clinical trial results and licensing agreements.

Sentiment Assessment: Overall sentiment is POSITIVE, with 4 out of 6 articles having a positive tone.

Catalyst Identification: Upcoming events include the Endocrine Society Annual Meeting (ENDO 2026) and the presentation of late-breaking data on Lorundrostat.

Market Narrative: The news headlines align with the technical signals, supporting the bullish trend.

Risk & Volatility Assessment

Beta Interpretation: Beta is low at 0.77, indicating that MLYS is less volatile than the market.

Volatility Regime: Current volatility is relatively low compared to historical levels.

Options Market Signals:

  • IV rank: 52.2% (Medium)
  • Put/call ratios: 1.51 (Bearish sentiment)

Market Context & Positioning

Sector Performance: MLYS performs similarly to the sector/market.

Institutional Activity: Institutional interest is moderate, with a volume flow ratio of 1.45.

Correlation Analysis: MLYS has a low correlation coefficient of 0.09 with the market.

Key Levels & Action Items

Critical Price Levels:

  • Support: $25.51
  • Resistance: $27.92

Breakout/Breakdown Levels: A breakout above $27.92 could trigger a significant move, while a breakdown below $25.51 could indicate increased selling pressure.

Time-Sensitive Catalysts: Earnings dates and regulatory approvals may impact the stock price in the near term.

Risk Management:

  • Stop-loss levels: consider setting stops at key support/resistance levels
  • Position sizing considerations: investors should be cautious of the high IV premium and potential volatility

By analyzing the data, we can see that MLYS has a bullish trend, supported by positive news headlines and technical indicators. However, there are risks to consider, including the high IV premium and potentially rich options prices. As such, investors should be cautious when entering this stock and consider risk management strategies to protect their positions.

Generated
News
Earnings History
8 of 8 under expected move
Avg Expected Move
21.95%
Avg Actual Move
4.88%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 After-Close 25.55% 2.12% 0.08x Within
2025-02-12 Pre-Market 46.46% 10.88% 0.23x Within
2025-05-12 After-Close 15.78% 1.04% 0.07x Within
2025-08-12 After-Close 15.44% 0.29% 0.02x Within
2025-11-10 Pre-Market 21.37% 16.81% 0.79x Within
2026-03-12 Pre-Market 15.89% 0.18% 0.01x Within
2026-05-06 After-Close 23.82% 6.73% 0.28x Within
2026-08-11 After-Close 11.25% 1.02% 0.09x Within
Options Activity
IV Rank (30D)
29.75
IV Rank (7D)
29.75
Avg IV
96.1%
Straddle (30D)
$3.97
Straddle (7D)
$3.97
P/C Volume
1.14
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.16
Correlation (SPY)
25.2%
R²
0.06
Ann. Volatility
59.8%
SPY Volatility
13.0%

Above average volatility - stock moves with market amplification

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 79,893,151 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

230 filers101,419,149 shares$2.71B value126.94% of float
# Filer Shares Value % of Total % of Float Period
1 Catalys Pacific, LLC 7,903,838 $213.25M 7.88% 9.89% 2026-06-30
2 RA CAPITAL MANAGEMENT, L.P. 7,692,750 $207.55M 7.67% 9.63% 2026-06-30
3 BlackRock, Inc. Custodian 5,887,038 $158.83M 5.87% 7.37% 2026-06-30
4 Samsara BioCapital, LLC 5,871,018 $158.40M 5.85% 7.35% 2026-06-30
5 FMR LLC Custodian 4,511,689 $121.73M 4.50% 5.65% 2026-06-30
6 VANGUARD GROUP INC Custodian 3,352,880 $121.68M 4.49% 4.20% 2025-12-31
7 STATE STREET CORP (STT, STT-PG) 4,141,636 $111.74M 4.13% 5.18% 2026-06-30
8 DEERFIELD MANAGEMENT COMPANY, L.P. 3,958,000 $106.79M 3.94% 4.95% 2026-06-30
9 VANGUARD CAPITAL MANAGEMENT LLC 2,756,770 $74.38M 2.75% 3.45% 2026-06-30
10 Laurion Capital Management LP 2,506,152 $67.62M 2.50% 3.14% 2026-06-30
11 ORBIMED ADVISORS LLC 2,110,300 $56.94M 2.10% 2.64% 2026-06-30
12 Capital World Investors 1,997,607 $53.90M 1.99% 2.50% 2026-06-30
13 ARMISTICE CAPITAL, LLC 1,736,000 $46.84M 1.73% 2.17% 2026-06-30
14 Troluce Capital Advisors LLC 1,728,753 $46.64M 1.72% 2.16% 2026-06-30
15 FRANKLIN RESOURCES INC Custodian 1,635,520 $44.13M 1.63% 2.05% 2026-06-30
16 Andera Partners 1,591,917 $42.95M 1.59% 1.99% 2026-06-30
17 GEODE CAPITAL MANAGEMENT, LLC Custodian 1,584,326 $42.75M 1.58% 1.98% 2026-06-30
18 SR ONE CAPITAL MANAGEMENT, LP 1,563,966 $42.20M 1.56% 1.96% 2026-06-30
19 BANK OF AMERICA CORP /DE/ Custodian 1,505,547 $40.62M 1.50% 1.88% 2026-06-30
20 SPHERA FUNDS MANAGEMENT LTD. 1,469,971 $39.66M 1.46% 1.84% 2026-06-30
21 GOLDMAN SACHS GROUP INC Custodian 1,458,676 $39.36M 1.45% 1.83% 2026-06-30
22 Pictet Asset Management Holding SA 1,430,649 $38.60M 1.43% 1.79% 2026-06-30
23 Polar Capital Holdings Plc 1,420,854 $38.33M 1.42% 1.78% 2026-06-30
24 MILLENNIUM MANAGEMENT LLC Custodian 1,221,758 $32.96M 1.22% 1.53% 2026-06-30
25 Ghisallo Capital Management LLC 1,125,000 $30.35M 1.12% 1.41% 2026-06-30
11 filers$46.41M notional
# Filer Notional Value % of Total Period
1 ARMISTICE CAPITAL, LLC $28.06M 60.46% 2026-06-30
2 Caption Management, LLC $3.88M 8.36% 2026-06-30
3 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $3.61M 7.78% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $3.30M 7.11% 2026-06-30
5 CITADEL ADVISORS LLC Custodian $2.05M 4.41% 2026-06-30
6 JANE STREET GROUP, LLC Custodian $1.91M 4.12% 2026-06-30
7 Troluce Capital Advisors LLC $1.35M 2.91% 2026-06-30
8 SIMPLEX TRADING, LLC Custodian $1.20M 2.59% 2026-06-30
9 MILLENNIUM MANAGEMENT LLC Custodian $841.78K 1.81% 2026-06-30
10 TUDOR INVESTMENT CORP ET AL $202.35K 0.44% 2026-06-30
11 Coastal Bridge Advisors, LLC $7.90K 0.02% 2026-06-30
7 filers$32.99M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $22.98M 69.65% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $4.82M 14.61% 2026-06-30
3 JANE STREET GROUP, LLC Custodian $1.70M 5.16% 2026-06-30
4 CITADEL ADVISORS LLC Custodian $1.42M 4.30% 2026-06-30
5 SIMPLEX TRADING, LLC Custodian $1.05M 3.18% 2026-06-30
6 GOLDMAN SACHS GROUP INC Custodian $914.62K 2.77% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $105.22K 0.32% 2026-06-30
Insider Activity
Latest: 2026-09-24
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-24 Brian Taylor Slingsby Director Sell (S) −104,320 $28.81 -$3.01M EDGAR
2026-09-22 Eric Warren Chief Commercial Officer Mixed — $20.68 -$110.7K EDGAR
2026-09-17 Daphne Karydas Director Mixed — $20.30 -$49.7K EDGAR
2026-08-25 Eric Warren Chief Commercial Officer Mixed — $19.61 -$94.7K EDGAR
2026-08-12 David Malcom Rodman Chief Medical Officer Mixed — $21.55 -$24.1K EDGAR
2026-08-12 James J. Ferguson III Chief Medical Officer Award (A) +102,400 — EDGAR
2026-07-23 Eric Warren Chief Commercial Officer Mixed — $20.06 -$101.4K EDGAR
2026-07-20 David Malcom Rodman Chief Medical Officer Mixed — $20.98 -$4.6K EDGAR
2026-07-15 Jon Congleton Chief Executive Officer Sell (S) −10,700 $27.24 -$291.4K EDGAR
2026-07-15 David Malcom Rodman Chief Medical Officer Mixed −6,349 $19.12 -$454.3K EDGAR
2026-07-10 David Malcom Rodman Chief Medical Officer Mixed — $23.15 -$31.0K EDGAR
2026-06-17 David Malcom Rodman Chief Medical Officer Mixed −6,348 $20.00 -$248.1K EDGAR
2026-06-17 Daphne Karydas Director Mixed — $18.51 -$38.9K EDGAR
2026-06-12 David Malcom Rodman Chief Medical Officer Mixed — $14.54 -$164.6K EDGAR
2026-05-19 David Malcom Rodman Chief Medical Officer Mixed — $21.50 -$5.0K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
17 insiders · @ $25.76
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Brian Taylor Slingsby Director 7,910,038 $203.76M -$86.06M 8 2026-02-20
2 SRINIVAS AKKARAJU Director 5,877,218 $151.40M $53.10M 8 2026-02-20
3 Samsara BioCapital, L.P. 10%+ Owner 5,674,916 $146.19M $16.20M 1 2025-03-17
4 RA Capital Nexus Fund III, L.P. Director 5,456,521 $140.56M $100.00M 3 2026-02-20
5 Samsara BioCapital GP, LLC 10%+ Owner 5,074,916 $130.73M $15.00M 1 2024-02-14
6 HBM Healthcare Investments (Cayman) Ltd. 10%+ Owner 3,218,106 $82.90M $5.00M 1 2023-02-16
7 RA Capital Healthcare Fund LP Director 1,867,229 $48.10M $87.50M 1 2025-03-17
8 RA CAPITAL MANAGEMENT, L.P. Director 1,867,229 $48.10M $150.00M 3 2025-09-08
9 Jon Congleton Chief Executive Officer 603,621 $15.55M -$15.36M 23 2026-07-15
10 James J. Ferguson III Chief Medical Officer 102,400 $2.64M $0 1 2026-08-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-09-22
Last 30d: 6 filings · $3.6M notice value  ·  Last 90d: 19 filings · $10.4M notice value · 5 unique filers · 95% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Warren Eric (4, $3.3M) · CATALYS PACIFIC FUND LP (1, $3.0M) · Congleton Jon (2, $2.3M) · Rodman David Malcom (11, $1.8M) · Karydas Daphne (1, $86K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-22 CATALYS PACIFIC FUND LP Director 104,320 $3.01M 2026-09-22 Morgan Stanley Smith Barney LLC … — EDGAR
2026-09-21 Warren Eric Officer 7,438 $209.1K 2026-09-21 Merrill Lynch 10b5-1 EDGAR
2026-09-17 Rodman David Malcom Officer 417 $11.7K 2026-09-17 Merrill Lynch 10b5-1 EDGAR
2026-09-15 Karydas Daphne Officer 3,000 $85.7K 2026-09-15 Merrill Lynch 10b5-1 EDGAR
2026-09-14 Rodman David Malcom Officer 7,709 $216.9K 2026-09-14 Merrill Lynch 10b5-1 EDGAR
2026-09-09 Rodman David Malcom Officer 2,171 $67.0K 2026-09-09 Merrill Lynch 10b5-1 EDGAR
2026-08-21 Warren Eric Officer 7,437 $193.2K 2026-08-21 Merrill Lynch 10b5-1 EDGAR
2026-08-17 Rodman David Malcom Officer 417 $10.6K 2026-08-17 Merrill Lynch 10b5-1 EDGAR
2026-08-13 Rodman David Malcom Officer 14,056 $372.2K 2026-08-13 Merrill Lynch 10b5-1 EDGAR
2026-08-10 Rodman David Malcom Officer 2,170 $58.8K 2026-08-10 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio4.3
EV/EBITDA-6.3
TTM Net Income$-0.3B
TTM EPS$-4.19
ROE-63.4%
Debt/Equity0.18